Mydecine Innovations Group Inc.
MYCOF
$0.0045
-$0.0006-11.77%
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -34.66% | 21.66% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -27.33% | 256.21% | |||
| Operating Income | 27.33% | -256.21% | |||
| Income Before Tax | 25.16% | -158.89% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 25.16% | -158.89% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 25.16% | -158.89% | |||
| EBIT | 27.33% | -256.21% | |||
| EBITDA | 27.36% | -257.29% | |||
| EPS Basic | 26.02% | -127.86% | |||
| Normalized Basic EPS | 26.00% | -127.27% | |||
| EPS Diluted | 26.02% | -127.86% | |||
| Normalized Diluted EPS | 26.00% | -127.27% | |||
| Average Basic Shares Outstanding | 0.92% | 13.73% | |||
| Average Diluted Shares Outstanding | 0.92% | 13.73% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
